UNSPSC 51431609: Verapamil

This classification denotes a calcium channel blocker with the molecular formula C27H38N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CJ0O37KU29, chemically known as 5-((3,4-dimethoxyphenethyl)methylamino)-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile but generally known as verapamil, which bears US NIH Compound Identifier 2520. European Medicines Agency schedules Verapamil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00038MIG.

UNSPSC 51431609 Verapamil is a Commodity code covering specific pharmaceutical products supplied to state and local health and emergency services. State and local governments are procuring verapamil and related advanced life support medications—calcium channel blockers and other cardiovascular agents—for emergency medical services, hospital systems, and pharmacy benefit programs. The code captures both direct supply agreements for emergency medications and broader pharmaceutical procurement frameworks that include verapamil as a line item within multi-source generic drug contracts. Issuing bodies include municipal fire and rescue departments, state health and human services agencies, and cooperative purchasing alliances serving state and local government facilities. The work spans transactional goods procurement (sealed bids for specific medication units with defined expiration and delivery terms) and strategic sourcing initiatives (cooperative purchasing vehicles and direct-to-manufacturer pharmacy programs that establish longer-term supply relationships across multiple jurisdictions).

Recent activity appears concentrated in Florida and Minnesota, with emerging state-level procurement in Texas. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) in April 2026 for Advanced Life Support Medications including verapamil-related products (diltiazem and other cardiac agents) for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000. The Minnesota Department of Administration's Office of State Procurement, acting through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted an RFP for Generic Multi Source Pharmaceuticals and OTC Products with a March 26, 2026 response date; awarded vendors will supply through three authorized wholesalers effective July 1, 2026, with a two-year contract term. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription models that would include verapamil and other medications outside traditional pharmacy benefit manager and wholesaler arrangements.